Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | See Remarks | July 15, 2025 | July 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date July 15, 2025 · Filed July 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 727,177 |
Reported balance
After 2025-07-15 transaction · row 1
1 source rowRow 1 · 2025-07-15 · Tax withholding · Disposed 5,154 · Balance 727,177 F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date December 31, 2018 · Filed February 07, 2019
Section 16 reporting ended · disclosed 2019-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| PRSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,929 |
Reported balance
After 2018-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-07 · Grant · Acquired 7,929 · Balance 7,929 F1: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Jul 16, 2025 16:21 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,154 | $2.59 | $13,348.86 |
DisclosureSEC source: 0001823239-25-000097 · wk-form4_1752697264.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 727,177 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:57 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 394,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-25-000053 · wk-form4_1742421473.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,331 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 17:27 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,886 | $2.64 | $15,539.04 |
DisclosureSEC source: 0001823239-25-000043 · wk-form4_1742419616.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,853 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 16:18 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 32,042 | $4.56 | $146,111.52 |
DisclosureSEC source: 0001823239-25-000010 · wk-form4_1737148693.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,739 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| July 15, 2024 Filed Jul 16, 2024 16:23 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,154 | $8.76 | $45,149.04 |
DisclosureSEC source: 0001823239-24-000089 · wk-form4_1721161412.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,781 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| April 30, 2024 Filed May 2, 2024 18:45 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 4,576 | $5.70 | $26,083.20 |
DisclosureSEC source: 0001823239-24-000052 · wk-form4_1714689934.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,935 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 4,576 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 17:56 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 6,714 | $7.70 | $51,697.80 |
DisclosureSEC source: 0001823239-24-000038 · wk-form4_1710798985.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,359 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:29 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 250,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-24-000014 · wk-form4_1705620559.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,073 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in one-half (1/2) increments on each of January 15, 2025, and January 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 31, 2023 Filed Nov 16, 2023 17:22 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 449 | $5.83 | $2,617.67 |
DisclosureSEC source: 0001823239-23-000097 · wk-form4_1700173332.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,796 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 449 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 16:50 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 5,578 | $12.52 | $69,836.56 |
DisclosureSEC source: 0001823239-23-000064 · wf-form4_168979982400912.xml · nonDerivative · entry 2 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,347 F2 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| April 28, 2023 Filed Jul 19, 2023 16:50 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 1,920 | $11.72 | $22,502.40 |
DisclosureSEC source: 0001823239-23-000064 · wf-form4_168979982400912.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,925 F1 · kind: The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 1,920 shares of Class A Common Stock was exempt pursuant to Rule 16b-3. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Options (Right to Buy) · Derivative | 143,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001823239-23-000029 · wf-form4_167908633193535.xml · derivative · entry 2 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-03-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 1/48th on April 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:52 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 72,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-23-000029 · wf-form4_167908633193535.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,005 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of March 15, 2024, March 15, 2025, and March 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:08 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Option (Right to Buy) · Derivative | 122,893 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001823239-22-000040 · wf-form4_165826131381082.xml · derivative · entry 2 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,893 Underlying: Class A Common Stock · 122,893 shares Expires 2032-07-15 F2 · derivative.exercise_date: Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 25% on July 15, 2023 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 16:08 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 63,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-22-000040 · wf-form4_165826131381082.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,498 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of July 15, 2023, July 15, 2024, and July 15, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 18:01 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,265 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045374 · doc4.xml · derivative · entry 3 Leddy Peter Michael · CIK 0001332202 · EVP, People and Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,265 Underlying: Common Stock · 2,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on August 3, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,265 shares on each of August 1, 2016, August 1, 2017 and August 1, 2018 and will vest as to 2,265 shares on August 1, 2019. F4 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on August 3, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,265 shares on each of August 1, 2016, August 1, 2017 and August 1, 2018 and will vest as to 2,265 shares on August 1, 2019. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 18:01 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 783 | $64.77 | $50,714.91 |
DisclosureSEC source: 0001209191-18-045374 · doc4.xml · nonDerivative · entry 2 Leddy Peter Michael · CIK 0001332202 · EVP, People and Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,018 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 342 shares acquired under the Issuer's employee stock purchase plan in October 2017 and 444 shares acquired under the Issuer's employee stock purchase plan in April 2018. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 18:01 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045374 · doc4.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · EVP, People and Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Amount includes 342 shares acquired under the Issuer's employee stock purchase plan in October 2017 and 444 shares acquired under the Issuer's employee stock purchase plan in April 2018. Read SEC document |
| February 07, 2018 Filed Feb 7, 2019 17:52 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 7,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008192 · doc5.xml · derivative · entry 1 Leddy Peter Michael · CIK 0001332202 · Former EVP, People and Culture 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Underlying: Common Stock · 7,929 shares Expires not disclosed F1 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2017. The award was granted with a performance condition based on the Issuer's earnings per share over the performance period ended December 31, 2017. On February 7, 2018, the Compensation Committee of the Issuer's Board of Directors certified the Issuer's performance for purposes of the award. Based on the Issuer's performance, the award will vest as to 7,929 shares on March 1, 2020, subject to and in accordance with the terms of the award. As the award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Due to an administrative error, a Form 4 reporting the certification of the performance condition was not filed in February 2018. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,265 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047485 · doc4.xml · derivative · entry 5 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,530 Underlying: Common Stock · 2,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on August 1, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,265 shares on each of August 1, 2016 and August 1, 2017 and will vest as to 2,265 shares on each of August 1, 2018 and August 1, 2019. F6 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on August 1, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,265 shares on each of August 1, 2016 and August 1, 2017 and will vest as to 2,265 shares on each of August 1, 2018 and August 1, 2019. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 851 | $64.43 | $54,829.93 |
DisclosureSEC source: 0001209191-17-047485 · doc4.xml · nonDerivative · entry 4 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 F4 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Issuer equity awards that have not yet vested. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047485 · doc4.xml · nonDerivative · entry 3 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Issuer equity awards that have not yet vested. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | PurchaseCommon Stock | 1,611 | $64.44 | $103,812.84 |
DisclosureSEC source: 0001209191-17-047485 · doc4.xml · nonDerivative · entry 2 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,336 F3 · price: Weighted average purchase price from purchase transactions ranging from $64.35 to $64.50. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Issuer equity awards that have not yet vested. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 17:58 UTC | NUVASIVE INC NUVA · Entity 110002 | PurchaseCommon Stock | 6,239 | $63.74 | $397,673.86 |
DisclosureSEC source: 0001209191-17-047485 · doc4.xml · nonDerivative · entry 1 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,725 F1 · price: Weighted average purchase price from purchase transactions ranging from $63.32 to $64.30. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to Issuer equity awards that have not yet vested. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 13,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009681 · doc4.xml · derivative · entry 1 Leddy Peter Michael · CIK 0001332202 · EVP Global HR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,203 Underlying: Common Stock · 13,203 shares Expires not disclosed F1 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.